Celgene announces acquisition of Delinia

Celgene has announced the acquisition of Delinia, a move that will expand its range of therapies for patients with autoimmune disorders.

Delinia is a biotechnology company developing novel therapeutics for a range of conditions, with its lead compound, DEL106, designed as a novel IL-2 mutein Fc fusion protein to preferentially upregulate regulatory T cells that help to maintain natural self-tolerance and immune system homeostasis.

This therapeutic approach is believed to have the potential to benefit patients with a variety of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.

Under the terms of the deal, Celgene will make an initial payment of $300 million (241.07 million pounds), with Delinia shareholders also eligible to receive up to an additional $475 million in contingent milestone-based payments.

Rupert Vessey, president of research and early development for Celgene, said: "Delinia is at the forefront of advancing new approaches to treating patients with severe and debilitating autoimmune diseases. We look forward to progressing DEL106 into the clinic next year."

It is expected that the transaction will close during the first quarter of the year.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.